BioCentury | Dec 4, 2020
Deals

Artios deal fourth for synthetic lethality in 2020: Data Byte

...well as double-digit option fees, $860 million in milestones per target, and double-digit royalties. In August,  Impact Therapeutics Inc. ...
...syndrome RecQ like helicase Karen Tkach Tuzman Artios Pharma Ltd. Merck KGaA Repare Therapeutics Inc. GlaxoSmithKline plc Ideaya Biosciences Inc. Bristol-Myers Squibb Co. Impact Therapeutics Inc. Shanghai...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

...impossible. Travel has almost stopped and you can’t move from city to city.” Jun Bao, Impact Therapeutics...
...have to rely on telecommunications,” said Jun Bao, president and CEO of Chinese cancer company Impact Therapeutics Inc....
...free to all who visit the site. Lauren Martz, Senior Editor dMed Biopharmaceutical Co. Ltd. Fountain Medical Development Ltd. Impact Therapeutics Inc. Coronavirus digital cov19pol cov19pol...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

...synthetic lethal interactions in patients with mutations in DDR pathway proteins BRCA1 and BRCA2. Shanghai-based Impact Therapeutics Inc.'s...
...hopes to list on the Hong Kong stock exchange or NASDAQ in 2022. COMPANY PROFILE Impact Therapeutics Inc....
...NYSE:AZN), London, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Beijing Shenogen Pharma Group Ltd., Beijing, China Impact Therapeutics Inc....
BioCentury | Aug 3, 2018
Financial News

Impact raises $30M series C

...Bioventure and Haibang Ventures as new investors. Lilly Asia Ventures also participated. Impact Therapeutics Inc., Nanjing, China Sandi Wong IMP4297 Impact Therapeutics Inc. Poly(ADP-ribose...
BioCentury | Aug 2, 2018
Financial News

Impact raises $30M series C

...Investment Fund, Sungent Bioventure and Haibang Ventures as new investors. Lilly Asia Ventures also participated. Sandi Wong IMP4297 Impact Therapeutics Inc. Poly(ADP-ribose...
BioCentury | Feb 29, 2016
Financial News

Impact Therapeutics completes venture financing

Impact Therapeutics Inc. , Nanjing, China Business: Cancer, Cardiovascular, Neurology Date completed: 2016-02-22 Type: Venture financing Raised: $10 million Investors: China Summit Capital; Guangzhou Yuexiu Industrial Investment Fund; Sungent BioVenture; Haibang Ventures; Lilly Asia Ventures Note:...
BioCentury | Feb 23, 2016
Financial News

Impact raises $10M in series B

...Cancer play Impact Therapeutics Inc. (Nanjing, China) said it raised about $10 million in a series B round...
Items per page:
1 - 7 of 7
BioCentury | Dec 4, 2020
Deals

Artios deal fourth for synthetic lethality in 2020: Data Byte

...well as double-digit option fees, $860 million in milestones per target, and double-digit royalties. In August,  Impact Therapeutics Inc. ...
...syndrome RecQ like helicase Karen Tkach Tuzman Artios Pharma Ltd. Merck KGaA Repare Therapeutics Inc. GlaxoSmithKline plc Ideaya Biosciences Inc. Bristol-Myers Squibb Co. Impact Therapeutics Inc. Shanghai...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

...impossible. Travel has almost stopped and you can’t move from city to city.” Jun Bao, Impact Therapeutics...
...have to rely on telecommunications,” said Jun Bao, president and CEO of Chinese cancer company Impact Therapeutics Inc....
...free to all who visit the site. Lauren Martz, Senior Editor dMed Biopharmaceutical Co. Ltd. Fountain Medical Development Ltd. Impact Therapeutics Inc. Coronavirus digital cov19pol cov19pol...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

...synthetic lethal interactions in patients with mutations in DDR pathway proteins BRCA1 and BRCA2. Shanghai-based Impact Therapeutics Inc.'s...
...hopes to list on the Hong Kong stock exchange or NASDAQ in 2022. COMPANY PROFILE Impact Therapeutics Inc....
...NYSE:AZN), London, U.K. Bayer AG (Xetra:BAYN), Leverkusen, Germany Beijing Shenogen Pharma Group Ltd., Beijing, China Impact Therapeutics Inc....
BioCentury | Aug 3, 2018
Financial News

Impact raises $30M series C

...Bioventure and Haibang Ventures as new investors. Lilly Asia Ventures also participated. Impact Therapeutics Inc., Nanjing, China Sandi Wong IMP4297 Impact Therapeutics Inc. Poly(ADP-ribose...
BioCentury | Aug 2, 2018
Financial News

Impact raises $30M series C

...Investment Fund, Sungent Bioventure and Haibang Ventures as new investors. Lilly Asia Ventures also participated. Sandi Wong IMP4297 Impact Therapeutics Inc. Poly(ADP-ribose...
BioCentury | Feb 29, 2016
Financial News

Impact Therapeutics completes venture financing

Impact Therapeutics Inc. , Nanjing, China Business: Cancer, Cardiovascular, Neurology Date completed: 2016-02-22 Type: Venture financing Raised: $10 million Investors: China Summit Capital; Guangzhou Yuexiu Industrial Investment Fund; Sungent BioVenture; Haibang Ventures; Lilly Asia Ventures Note:...
BioCentury | Feb 23, 2016
Financial News

Impact raises $10M in series B

...Cancer play Impact Therapeutics Inc. (Nanjing, China) said it raised about $10 million in a series B round...
Items per page:
1 - 7 of 7